Department of Dermatology, Saint-Eloi Hospital and Montpellier University Hospital, 34295 Montpellier, France.
Acta Derm Venereol. 2019 Mar 1;99(3):256-262. doi: 10.2340/00015555-3091.
Anti-transcriptional intermediary factor-1γ (TIF-1γ) autoantibody may be associated with cancer in adult patients with dermatomyositis. The aim of this study was to evaluate the risk of cancer in the presence of anti-TIF-1γ autoantibody in adult dermatomyositis. A comprehensive database search of EMBASE, MEDLINE and the Cochrane Library up to May 2018 was performed using the main key words "dermatomyositis", ""myositis", "inflammatory myopathies" and "anti-TIF-1". Eighteen studies, with a total of 1,962 dermatomyositis, were included in the meta-analysis. The pooled prevalence of cancer-associated dermatomyositis in patients with anti-TIF-1γ autoantibody was 0.41 (95% confidence interval (CI) 0.36-0.45). In the presence of anti-TIF-1γ autoantibody, the overall diagnostic odds ratio of cancer was 9.37 (95% CI 5.37-16.34) with low heterogeneity (Cochran's Q: 14.88 (df = 17, p = 0.604); I2 = 0%). The results of this systematic review confirm that detection of anti-TIF-1γ autoantibody is a valuable tool to identify a subset of adult dermatomyositis patients with higher risk of cancer.
抗转录中介因子-1γ（TIF-1γ）自身抗体可能与成人皮肌炎患者的癌症有关。本研究旨在评估成人皮肌炎中存在抗 TIF-1γ 自身抗体时的癌症风险。通过主要关键词“皮肌炎”、“肌炎”、“炎症性肌病”和“抗 TIF-1”，对 EMBASE、MEDLINE 和 Cochrane 图书馆进行了全面的数据库检索，检索截至 2018 年 5 月。共有 18 项研究，共计 1962 例皮肌炎患者纳入荟萃分析。抗 TIF-1γ 自身抗体阳性患者中与癌症相关的皮肌炎的总患病率为 0.41（95%置信区间 0.36-0.45）。在存在抗 TIF-1γ 自身抗体的情况下，癌症的总体诊断比值比为 9.37（95%置信区间 5.37-16.34），异质性较低（Cochran's Q：14.88（df=17，p=0.604）；I2=0%）。本系统评价的结果证实，检测抗 TIF-1γ 自身抗体是识别具有更高癌症风险的成人皮肌炎患者亚组的有价值工具。
